Page last updated: 2024-10-17

phosphonoacetic acid and Breast Neoplasms

phosphonoacetic acid has been researched along with Breast Neoplasms in 13 studies

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"Cultured wild-type MCF-7 human breast cancer cells and two MCF-7 sublines that overproduce enzymes of the de novo pyrimidine biosynthetic pathway were compared with regard to: rate of de novo biosynthesis of uracil nucleotides, sensitivity of the de novo and salvage pathways to the concentration of intracellular uracil nucleotides, and potential of exogenous uridine at concentrations equivalent to plasma levels to affect de novo pyrimidine biosynthesis."3.67Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. ( Chisena, CA; Cowan, KH; Cysyk, RL; Karle, JM, 1986)
"Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously."2.67A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991)
"Sixty-three patients with Stage IV breast carcinoma refractory to standard combination chemotherapy agents such as 5-fluorouracil (5-FU) were entered into a study to determine the efficacy of a multiple dose schedule of N-(phosphonacetyl)-L-aspartic acid (PALA) and whether the addition of PALA improves the therapeutic efficacy of 5-FU."2.66A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. ( Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY, 1985)
"One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen."1.26Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982)
"Thirty-three patients with advanced breast cancer were treated with PALA at a schedule of 1500 mg/m2/day for 5 days every 3 weeks."1.26PALA in advanced breast cancer. A phase II pilot study by the ECOG. ( Davis, TE; Falkson, G; Keller, AM; Taylor, SG, 1982)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19907 (53.85)18.7374
1990's5 (38.46)18.2507
2000's0 (0.00)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lacerda-Abreu, MA1
Russo-Abrahão, T1
Cosentino-Gomes, D1
Nascimento, MTC1
Carvalho-Kelly, LF1
Gomes, T1
Rodrigues, MF1
König, S1
Rumjanek, FD1
Monteiro, RQ1
Meyer-Fernandes, JR1
Ying, H1
Subrata, S1
Paridaens, R1
Mouridsen, HT1
Palshof, T1
Cocconi, G1
Van Oosterom, A1
Rotmensz, N1
Sylvester, R1
Heuson, JC1
Rozencweig, M1
Ardalan, B3
Jamin, D1
Jayaram, HN2
Presant, CA1
Weiss, GR1
Ervin, TJ1
Meshad, MW1
Kufe, DW1
Taylor, SG1
Davis, TE1
Falkson, G1
Keller, AM1
Glazer, RI1
Kensler, TW1
Van Pham, T1
Macdonald, JS1
Cooney, DA1
Gudas, JM1
Nguyen, H1
Li, T1
Sadzewicz, L1
Robey, R1
Wosikowski, K1
Cowan, KH2
Santos, O1
Pant, KD1
Blank, EW1
Ceriani, RL1
Sridhar, KS1
Benedetto, P1
Richman, S1
Waldman, S1
Morrell, L1
Feun, L1
Savaraj, N1
Fodor, M1
Livingstone, A1
Allegra, CJ1
Karle, JM1
Chisena, CA1
Cysyk, RL1
Mann, GB1
Hortobagyi, GN1
Buzdar, AU1
Yap, HY1
Valdivieso, M1

Trials

2 trials available for phosphonoacetic acid and Breast Neoplasms

ArticleYear
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Cancer, 1991, Sep-15, Volume: 68, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B

1991
A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Cancer, 1985, Sep-15, Volume: 56, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female

1985

Other Studies

11 other studies available for phosphonoacetic acid and Breast Neoplasms

ArticleYear
H
    Biochimica et biophysica acta. Molecular basis of disease, 2019, 09-01, Volume: 1865, Issue:9

    Topics: Breast Neoplasms; Cadherins; Cell Adhesion; Cell Line; Cell Proliferation; Down-Regulation; Female;

2019
[S-phase arrest associated apoptosis leads to diversities of drug resistance and mutation rate in human breast cancer cells].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 1999, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Breast Neoplasms; Drug Resistance, Neoplasm; Humans

1999
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Breast Neoplasms; Digestive System; Dru

1982
Phase I study of continuous-infusion PALA and 5-FU.
    Cancer treatment reports, 1984, Volume: 68, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti

1984
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th

1982
PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    American journal of clinical oncology, 1982, Volume: 5, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Breast Neoplasms; Digestive System;

1982
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
    Biochemical pharmacology, 1981, Aug-01, Volume: 30, Issue:15

    Topics: Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Division; Cell Line; Drug Synergism; Fe

1981
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
    Carcinogenesis, 1996, Volume: 17, Issue:7

    Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone

1996
5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:8

    Topics: Animals; Aspartic Acid; Breast Neoplasms; Deoxycytidine; Drug Therapy, Combination; Humans; Idoxurid

1992
Biochemical modulation: a modality that has come of therapeutic age.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brea

1991
Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
    Molecular pharmacology, 1986, Volume: 30, Issue:2

    Topics: Amides; Aspartate Carbamoyltransferase; Aspartic Acid; Breast Neoplasms; Carbamoyl-Phosphate Synthas

1986